Drugs / LY2624803
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01257178 | Nov 2010 | insomnia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01236105 | Oct → Dec 2010 | insomnia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01784614 | Sep 2009 → Mar 2010 | sleep disorder, initiating and maintaining sleep | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01779830 | May → Nov 2008 | insomnia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00784875 | Oct 2008 → Feb 2010 | insomnia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2624803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01779830 ↗ |
| Known as | HY-10275 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314393 ↗ |
| Known as | HY10275 BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314393 ↗ |
| Action | Inhibit | “Histamine H1 receptor antagonist” CHEMBL5314393 ↗ |
| Modality | Small molecule | — CHEMBL5314393 ↗ |
| Route | Oral | “1 mg, oral capsule, once nightly before bedtime” NCT00784875 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL5314393 ↗ |